Compare Nuscale Power Corporation (SMR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs GeneDx Holdings Corp — how do they compare? Nuscale Power Corporation trades at $8.82 (market cap $2.76B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Nuscale Power Corporation is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| SMR | WGS | |
|---|---|---|
Market Cap | $2.76B | $1.80B |
Sector | Utilities | Technology |
52-Week High | $53.43 | $167.51 |
52-Week Low | $7.64 | $34.51 |
Enterprise Value | $1.87B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company shows severe fundamental challenges with negative net income margins exceeding -2,000% and consecutive earnings misses. Despite these losses, analyst consensus remains optimistic with a $12.25 price target representing 54% upside potential, driven by nuclear energy's long-term prospects and the company's first-mover advantage in small modular reactors.
The stock presents a high-risk, high-reward opportunity. While current financials are deeply concerning with massive losses and negative cash flow, the potential nuclear energy renaissance and SMR's regulatory approvals offer substantial upside if commercialization succeeds. Investors face significant execution risk as the company burns cash while attempting to secure its first commercial reactor sale.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
